162 related articles for article (PubMed ID: 37533208)
21. Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B.
Jung YW; Kim M; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
J Korean Med Sci; 2020 May; 35(17):e104. PubMed ID: 32356416
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
Zhou TC; Lai X; Feng MH; Tang Y; Zhang L; Wei J
J Viral Hepat; 2018 Oct; 25(10):1172-1179. PubMed ID: 29741285
[TBL] [Abstract][Full Text] [Related]
23. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
24. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis.
Yilmaz B; Koklu S; Buyukbayram H; Yalçin K; Korkmaz U; Posul E; Can G; Kurt M
Afr Health Sci; 2015 Sep; 15(3):714-8. PubMed ID: 26957957
[TBL] [Abstract][Full Text] [Related]
25. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020.
van der Spek DPC; Katwaroe WK; van Kleef LA; Brakenhoff S; de Man RA; de Knegt RJ; van der Meer AJ; Sonneveld MJ
Eur J Intern Med; 2023 Jan; 107():86-92. PubMed ID: 36396524
[TBL] [Abstract][Full Text] [Related]
26. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.
Peng D; Han Y; Ding H; Wei L
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1082-8. PubMed ID: 18707599
[TBL] [Abstract][Full Text] [Related]
27. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.
Fan R; Niu J; Ma H; Xie Q; Cheng J; Rao H; Dou X; Xie J; Zhao W; Peng J; Gao Z; Gao H; Chen X; Chen J; Li Q; Tang H; Zhang Z; Ren H; Cheng M; Liang X; Zhu C; Wei L; Jia J; Sun J; Hou J;
Aliment Pharmacol Ther; 2021 Aug; 54(3):329-338. PubMed ID: 34157146
[TBL] [Abstract][Full Text] [Related]
28. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
[TBL] [Abstract][Full Text] [Related]
29. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
30. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
Chang X; Li Y; Sun C; Li X; Du W; Shang Q; Song L; Long Q; Li Q; Liu H; Wang J; Yu Z; Li J; Xiao G; Li L; Chen L; Tan L; Chen Y; Yang Y
J Gastroenterol; 2023 May; 58(5):481-493. PubMed ID: 36928343
[TBL] [Abstract][Full Text] [Related]
31. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
[TBL] [Abstract][Full Text] [Related]
33. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B.
Wong SW; Chan WK; Mohamed R
J Viral Hepat; 2020 Dec; 27(12):1297-1305. PubMed ID: 32668489
[TBL] [Abstract][Full Text] [Related]
34. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
35. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.
Lesmana LA; Lesmana CR; Pakasi LS; Krisnuhoni E
Acta Med Indones; 2012 Jan; 44(1):35-9. PubMed ID: 22451183
[TBL] [Abstract][Full Text] [Related]
37. Management of chronic hepatitis B.
Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
[TBL] [Abstract][Full Text] [Related]
38. Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression.
Pokorska-Śpiewak M; Kowalik-Mikołajewska B; Aniszewska M; Pluta M; Walewska-Zielecka B; Marczyńska M
Medicine (Baltimore); 2017 Jan; 96(3):e5832. PubMed ID: 28099338
[TBL] [Abstract][Full Text] [Related]
39. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
40. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
